Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

ratiopharm gmbh - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminika pro systémové použití, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - imunologická vyšetření pro suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. dalším klíčovým přispěvatelem k odřeninám, skatolem, může být i nepřímý účinek. agresivní a sexuální (montážní) chování jsou také sníženy. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

serono europe limited - efalizumab - psoriáza - imunosupresiva - léčba dospělých pacientů se středně těžkou až těžkou chronickou ložiskovou psoriázou, kteří nedostatečně reagovali na, nebo kteří mají kontraindikovanou nebo netolerují léčbu včetně cyklosporinu, methotrexátu a puva (viz bod 5. 1 - klinická účinnost).

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriáza - imunosupresiva, inhibitory interleukinu, - ilumetri je indikován k léčbě dospělých se středně těžkou až těžkou ložiskovou psoriázou, kteří jsou kandidáty pro systémovou léčbu.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastická činidla - poteligeo je indikován k léčbě dospělých pacientů s mycosis fungoides (mf), nebo sézary syndrom (ss), kteří obdrželi alespoň jedna předchozí systémová terapie.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat fosfát - cushingův syndrom - kortikosteroidy pro systémové použití - isturisa je indikován k léčbě endogenního cushingova syndromu u dospělých.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

novo nordisk a/s - semaglutid - obesity; overweight - preparáty proti obezitě, diety - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriáza - imunosupresiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

leo pharma a/s, ballerup array - 16569 monohydrÁt kalcipotriolu; 2065 betamethason-dipropionÁt - kožní pěna - 50mcg/g+0,5mg/g - kalcipotriol, kombinace

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.